How a Healthcare Platform Turned Off-Limits Data Into Revenue

The platform was sitting on a large, valuable clinical dataset riddled with the most sensitive categories of protected health information, including substance-use-disorder data governed by 42 CFR Part 2, which is far stricter than ordinary HIPAA PHI. That sensitivity made the data effectively untouchable: it could not be shared, analyzed with outside tools, or monetized without enormous legal exposure. A real revenue asset was trapped behind compliance risk.

OutcomeCatalyst built a de-identification layer that safely strips and protects both standard PHI and the extra-restricted SUD / Part 2 data inside a compliant environment — turning records that were legally radioactive into clean, structured data the business could actually use and package.

The platform's clinical dataset was valuable but effectively untouchable: it carried the most sensitive categories of PHI, including substance-use-disorder data governed by 42 CFR Part 2, which is far stricter than ordinary HIPAA. The project initially scoped de-identifying structured PHI, but mid-way the team discovered the data was far messier than the client realized — sensitive categories, including PHI-SUD data, were tangled inside clinical free-text notes, each carrying a different handling and compliance burden. OutcomeCatalyst built a de-identification layer that strips and protects both standard PHI and the extra-restricted Part 2 / SUD data — including what was buried in free text — inside a compliant environment. The work treated compliance as the unlock rather than the obstacle, engineering the output to be clean, structured, and safe to use and package. With the legal risk removed, data that had been pure liability became an asset the business could actually put to work.

Healthcare platforms, payers, and life-sciences firms holding sensitive clinical datasets (including 42 CFR Part 2 / SUD data) that are blocked from analysis or monetization by compliance risk.